Navigation Links
Spectral announces third quarter 2008 results
Date:11/12/2008

TORONTO, Nov. 12 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced its financial results for the third quarter ended September 30, 2008.

"In September, Spectral took a major first step in the implementation of its strategy to align its diagnostic with a therapeutic for the treatment of severe sepsis. We agreed, with Toray Industries Inc., to key terms for the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream and has been used safely and effectively in over 70,000 patients in Japan and Europe since 1994," said Dr. Paul Walker, President and CEO of Spectral. "Combined with our Endotoxin Activity Assay, EAA(TM), the only FDA cleared diagnostic for the detection of endotoxin, we believe that this treatment can fulfill a major unmet need for the approximately 100,000 patients with elevated endotoxin levels that develop severe sepsis or septic shock in the U.S. each year."

Dr. Walker added: "We are in the process of completing our due diligence and we plan to meet with the U.S. FDA early in the first quarter to determine an appropriate clinical development pathway. Following the FDA's clearance of our clinical pathway, we expect to finalize the exclusive license and material supply agreements with Toray in the first quarter of 2009."

Financial Review

For the three months ended September 30, 2008, Spectral reported sales of $701,000 compared to $739,000 for the corresponding period in 2007. For the nine months ended September 30, 2008, the Company reported sales of $2,150,000, compared to sales of $2,318,000 for the same period last year. Sales of the Company's EAA(TM) diagnostic increased significantly, but the improvement was offset by lower royalty revenues. Certain pre-established royalty plateaus were reached in 2007, resulting in a reduction of $466,000 in related revenues for the first nine mon
'/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spectral to bring anti-sepsis therapy to the U.S. market
2. Spectral announces exclusive distribution agreement in Russia for its EAA(TM) Sepsis Diagnostic Assay
3. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
4. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
5. Spectral and Toray expand collaboration to include new geographic territories
6. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectral announces 2007 financial results
9. Spectral appoints Anthony Bihl to Board of Directors
10. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
11. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... 1000 balances – 4 steps – ... weighing needs and expertly narrows down the mass of ... or even terminals. , First, select the working ... select readability instead) and define the accuracy – it’s ... narrows down the list to models that fit best ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... Lumidigm, Inc. is proud to announce that its ... technologies and products recognized by Popular Science as ... Venus product is the first high-volume multispectral imaging ... ease of integration, the Venus fingerprint sensor features ...
... LAUSANNE, Switzerland and BANGALORE, India, November ... biopharmaceutical development,specialist that focuses on serious ... Discovery Technologies Ltd (Aurigene), a,Bangalore-based fully ... molecule,and peptide drug discovery and development ...
... (OTC Bulletin Board: SYMD) announced today that it has ... membrane intended to prevent post-operative adhesions in nasal and ... and sinus procedures performed annually in the United States. ... P. Hickey, SyntheMed,s President & CEO stated, "SinusShield represents ...
Cached Biology Technology: Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 2 Lumidigm Biometric Sensor Included in Popular Science Best of What's New for 2008 : Venus Series Fingerprint Sensor Called a Breakthrough Product by the World's Largest Science and Technology Magazine 3Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 2Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway 3SyntheMed Announces FDA Clearance of SinusShield(TM) 2
(Date:7/25/2014)... bifda (SB) is a complex congenital central nervous ... closing of the neural tubes during the embryonic ... urinary and fecal incontinence and neurocognitive retardation. Such ... quality of life. Researchers at Ankara Physical Medicine ... the functional performance in children with SB, using ...
(Date:7/25/2014)... first time, Spanish researchers have detected an unknown interaction ... cells are introduced into a droplet of salt water ... chloride crystallisation to create biomineralogical biosaline 3D morphologically complex ... material, bacteria are revived. The discovery was made by ... cover of the Astrobiology journal and may ...
(Date:7/24/2014)... July 24, 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, ... devices, has cut emergency room wait times by an ... (UCSD) Medical Center, according to a recent study published ... Departments are using the suite to access data from ... defibrillators. "Using Geneva,s technology platform we have ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3
... The leaking of environmentally damaging pollutants into our waters ... mathematical algorithm, according to researchers. Presenting their research ... Problems , the researchers, from Universit de Technologie ... avoid environmental catastrophes by identifying the exact location where ...
... renowned biologist and population geneticist, has been named founding ... This newly created position will further strengthen GW,s role ... region and nationally. As director, Dr. Crandall ... Institute and direct the development and implementation of research ...
... as an important predictor of survival among human patients with ... Veterinary Medicine at Tufts University have developed two surveys that ... of life for dogs and cats with heart disease. ... (Cats, Assessment Tool for Cardiac Health), the surveys ask owners ...
Cached Biology News:Maths formula leads researchers to source of pollution 2GW announces creation of Computational Biology Institute to conduct integrated research 2GW announces creation of Computational Biology Institute to conduct integrated research 3GW announces creation of Computational Biology Institute to conduct integrated research 4New tools for evaluating quality of life for cats, dogs with heart disease 2
...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... antibody raised against a partial ... Immunogen: HD (NP_002102, 81 ... recombinant protein with GST tag. ... NM_002111 ...
Biology Products: